Skip to main content
. Author manuscript; available in PMC: 2021 Oct 1.
Published in final edited form as: Mol Cancer Res. 2020 Dec 18;19(4):623–635. doi: 10.1158/1541-7786.MCR-20-0949

Figure 1. Copy number alterations and somatic mutations in the DCIS-to-IDC transition.

Figure 1.

A, Genome-wide summary of proportion of patients with observed CNAs in the Recurrence (our data), Abba (5), and Lesurf (16) cohorts. A z-score of 2 in GATK CNV was set to call gains and losses in the recurrence and Abba cohorts (exome-seq), and a threshold of ±0.3 in the Lesurf set (aCGH). Both DCIS and IDC samples are shown in the recurrence cohort. B, Summary of CNAs in breast cancer-associated oncogenes and tumor suppressors in the recurrence cohort. C, Summary of cancer-related CNAs and coding mutations in the recurrence cohort, and corresponding gene expression profiles. D, variants found in adjacent normal mammary tissue. E, Summary of cancer-related CNAs and mutations in the Abba and Lesurf cohorts grouped by PAM50 subtype. F, Pathways implicated by genetic changes in all three cohorts and by RNA-expression in the Abba cohort comparing DCIS to normal. Circle size reflective of the average enrichment score and line width reflective of the number of common genes in two pathways.